Trial Profile
Single-centre Open Label Exploratory Phase IIb Pilot Study of Exogenous Oral Melatonin for the Treatment of Nocturia in Adults With Parkinson's Disease
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 06 Nov 2021
Price :
$35
*
At a glance
- Drugs Melatonin (Primary)
- Indications Nocturia
- Focus Therapeutic Use
- 30 Jul 2020 Status changed from recruiting to completed.
- 17 Mar 2016 Status changed from not yet recruiting to recruiting as reported by United Kingdom Clinical Research Network record.
- 17 Feb 2015 New trial record